PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Darapladib falls short in chronic coronary heart disease

Investigational drug targets inflammation's role in clogged arteries

2014-03-31
(Press-News.org) WASHINGTON (March 30, 2014) — The novel inflammation inhibitor darapladib showed no primary-endpoint advantage over placebo in patients with chronic coronary heart disease treated with a high level of background care, although it did suggest possible benefits for more specific coronary artery-related endpoints, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. STABILITY is the first study to test this inflammation-prevention mechanism for reducing the likelihood that plaque will become an artery-blocking clot.

Darapladib strongly inhibits Lp-PLA2, a biomarker of inflammation in blood vessels. In the bloodstream, Lp-PLA2 is generally found on LDL cholesterol. High Lp-PLA2 levels are a risk factor for coronary heart disease and, in animal models, are linked with vulnerable plaque, an unstable waxy buildup in arterial walls that is associated with heart attacks and strokes.

In this international, phase III double-blind trial, 15,828 patients with chronic coronary heart disease (median age 65 years) were randomly assigned to receive a 160-mg darapladib tablet or placebo once daily. No major safety concerns arose; median follow-up was 3.7 years. The primary endpoint of time to first heart attack, stroke and death from cardiovascular causes was not met. Darapladib showed no significant benefit, with 769 events (9.7 percent) compared with 819 events (10.4 percent) for placebo. However, a secondary endpoint looking at a reduction in major coronary events related to the arteries (heart attack, urgent need for angioplasty or bypass surgery, or death) was nominally significant. The darapladib group had a 10 percent relative risk reduction, with 737 events (9.3 percent) in major coronary events compared with 814 events (10.3 percent) in the placebo group.

"These events are clinically important, with substantial consequences for patients," said Harvey D. White, M.D., director of Coronary Care Unit, Green Lane Cardiovascular Unit, Auckland City Hospital, New Zealand, and a co-chair of the study. "The effects on these endpoints could support the hypothesis that inhibition of Lp-PLA2 with darapladib may alter the composition of atherosclerotic plaques to a less vulnerable state and reduce ischemic events related to coronary artery plaque progression and rupture."

Researchers were surprised to see the high rate of background care in this patient population. At baseline, 93 percent of patients were taking aspirin, 97 percent statins, 79 percent beta-blockers and 77 percent ACE inhibitors or angiotensin receptor blockers, compared with similar rates at the end of the study. "We set out to test the incremental effect of darapladib on top of optimal treatment," White said.

One intriguing finding emerged from subgroup analyses: smokers had a greater decrease in major adverse cardiovascular events than non-smokers. "Previous studies showed that smokers have higher Lp-PLA2 levels, and it's plausible that smokers may be more responsive to Lp-PLA2 inhibition, but this finding may have occurred by chance and should be considered hypothesis generating," White said.

Ongoing analysis of biomarkers, including Lp-PLA2 levels, and genetic sub-studies of STABILITY may help provide insight about darapladib's potential effects on the prevention of coronary events in patients with stable coronary heart disease. "As with statins, it may take some time for the anti-inflammatory effect of darapladib to alter the composition of coronary artery plaque, resulting in less vulnerability and fewer coronary events," White said. The modest effect of darapladib on coronary artery-related events seen in this study may heighten interest in SOLID-TIMI 52, a phase III study of darapladib in patients with recent experience of acute coronary disease.

INFORMATION: The study was funded by GlaxoSmithKline.

This study will be simultaneously published online in the New England Journal of Medicine at the time of presentation.

The ACC's Annual Scientific Session brings together cardiologists and cardiovascular specialists from around the world each year to share the newest discoveries in treatment and prevention. Follow @ACCMediaCenter and #ACC14 for the latest news from the meeting. The American College of Cardiology is a nonprofit medical society comprised of 47,000 physicians, surgeons, nurses, physician assistants, pharmacists and practice managers. The College is dedicated to transforming cardiovascular care, improving heart health and advancing quality improvement, patient-centered care, payment innovation and professionalism. The ACC also leads the formulation of important cardiovascular health policy, standards and guidelines. It bestows credentials upon cardiovascular specialists, provides professional education, supports and disseminates cardiovascular research, and operates national registries to measure and promote quality care. For more information, visit CardioSource.org.


ELSE PRESS RELEASES FROM THIS DATE:

Evolocumab safely drops LDL cholesterol well below statin-only baseline

2014-03-31
WASHINGTON (March 30, 2014) — The monoclonal antibody evolocumab produced highly significant reductions in low-density lipoprotein (LDL) cholesterol, the "bad cholesterol," as an add-on to statins in all treatment groups, according to data from the LAPLACE-2 study presented at the American College of Cardiology's 63rd Annual Scientific Session. LDL cholesterol is considered a major risk factor for cardiovascular disease. "High-risk patients – such as those with clinical cardiovascular disease, high LDL cholesterol levels or diabetes – are ideally treated with high-intensity ...

Anti-gout medication colchicine helps patients with recurrent pericarditis

2014-03-31
WASHINGTON (March 30, 2014) — A medication traditionally used to treat gout is also effective at treating recurrent pericarditis, an inflammation of the sac-like covering around the heart, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. In the first multicenter, double-blind trial to look at the use of colchicine for multiple recurrences of pericarditis, 240 patients were randomly assigned to either the study drug or placebo to examine the primary endpoint of recurrent pericarditis. The rate of disease recurrence ...

Renal denervation patient registry finds low rate of adverse events

2014-03-31
WASHINGTON (March 30, 2014) — Patients with uncontrolled high blood pressure treated with renal denervation had low rates of adverse events and significant lowering of blood pressure at six months, according to a registry-based study presented at the American College of Cardiology's 63rd Annual Scientific Session. The Global SYMPLICITY Registry is the first and largest dataset of patients with uncontrolled hypertension treated with renal denervation. The open-label, multicenter study was established to examine the safety and effectiveness of the procedure. Outcomes presented ...

Post-approval study of transcatheter pulmonary valve completes 1 year

2014-03-31
WASHINGTON (March 30, 2014) — The first post-FDA approval study of a non-surgically implanted replacement pulmonary valve showed strong short- and mid-term results for the device in a small sample of patients with certain congenital heart defects, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. This multi-center study of 100 patients consecutively implanted with the Melody transcatheter pulmonary valve between July 2010 and July 2012 assessed the effectiveness of the device at six and 12 months based on the percentage ...

Cardiac resynchronization improves survival in heart failure patients

2014-03-31
WASHINGTON (March 30, 2014) — Patients in mild heart failure who receive a specialized pacemaker known as cardiac resynchronization therapy with a defibrillator (CRT-D) may live longer than those implanted with a traditional implantable cardioverter defibrillator (ICD), according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. In the first study to look at CRT-D in mildly symptomatic patients, researchers found that patients with left bundle branch block implanted with a CRT-D had a 41 percent reduced risk of death compared ...

Blood test helps predict heart attack risk for patients with chest pain

2014-03-31
WASHINGTON (March 30, 2014) — Patients presenting to the emergency department with an undetectable level of the blood biomarker high-sensitivity cardiac troponin T, and whose ECGs show no sign of restricted blood flow, have a minimal risk of heart attack within 30 days, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. In a study of all patients (14,636 in total) reporting to a Swedish emergency department with chest pain over a two-year period from 2010 to 2012, researchers examined patients' blood levels of high-sensitivity ...

The Atlantic Ocean dances with the sun and volcanoes

2014-03-31
Imagine a ballroom in which two dancers apparently keep in time to their own individual rhythm. The two partners suddenly find themselves moving to the same rhythm and, after a closer look, it is clear to see which one is leading. It was an image like this that researchers at Aarhus University were able to see when they compared studies of solar energy release and volcanic activity during the last 450 years, with reconstructions of ocean temperature fluctuations during the same period. The results actually showed that during the last approximately 250 years – since ...

Researchers reveal a new pathway through the sodium pump

Researchers reveal a new pathway through the sodium pump
2014-03-31
A study in The Journal of General Physiology provides new evidence that the ubiquitous sodium pump is more complex—and more versatile—than we thought. The sodium pump is present in the surface membrane of all animal cells, using energy derived from ATP to transport sodium and potassium ions in opposite directions across the cell boundary. By setting up transmembrane gradients of these two ions, the pump plays a vital role in many important processes, including nerve impulses, heartbeats, and muscular contraction. Now, Rockefeller University researchers Natascia Vedovato ...

Data show benefit of comprehensive lipid testing in determining risk for coronary heart disease

2014-03-31
Washington, D.C., March 31, 2014 ― Data presented from two meta-analyses using the Atherotech Vertical Auto Profile (VAP®) Lipid Panel showed the impact high-density lipoprotein (HDL) cholesterol and remnant lipoprotein (RLP) cholesterol have on determining a patient's risk for hard coronary heart disease (CHD) endpoints, such as myocardial infarction or coronary death. Each analysis examined men and women without prevalent CHD enrolled in both the Framingham Offspring and Jackson Heart studies over eight years. In both studies, HDL, the "good" cholesterol in the ...

Giving steroids during bypass surgery shows no benefit, some harm

2014-03-31
WASHINGTON (March 31, 2014) — Giving patients steroids at the time of heart surgery does not improve health outcomes and appears to put them at greater risk of having a heart attack in the days following surgery, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. The finding, which stems from the largest randomized trial in cardiac surgery ever conducted, challenges a practice that many surgeons have used for decades. "Based on these results, we suggest that steroids should not be used prophylactically during cardiac ...

LAST 30 PRESS RELEASES:

Community partners key to success of vaccine clinic focused on neurodevelopmental conditions

Low-carbon collaborative dual-layer optimization for energy station considering joint electricity and heat demand response

McMaster University researchers uncover potential treatment for rare genetic disorders

The return of protectionism: The impact of the Sino-US trade war

UTokyo and NARO develop new vertical seed distribution trait for soybean breeding

Research into UK’s use of plastic packaging finds households ‘wishcycle’ rather than recycle – risking vast contamination

Vaccine shows promise against aggressive breast cancer

Adverse events affect over 1 in 3 surgery patients, US study finds

Outsourcing adult social care has contributed to England’s care crisis, argue experts

The Lancet: Over 800 million adults living with diabetes, more than half not receiving treatment, global study suggests

New therapeutic approach for severe COVID-19: faster recovery and reduction in mortality

Plugged wells and reduced injection lower induced earthquake rates in Oklahoma

Yin selected as a 2024 American Society of Agronomy Fellow

Long Covid could cost the economy billions every year

Bluetooth technology unlocks urban animal secrets

This nifty AI tool helps neurosurgeons find sneaky cancer cells

Treatment advances, predictive biomarkers stand to improve bladder cancer care

NYC's ride-hailing fee failed to ease Manhattan traffic, new NYU Tandon study reveals

Meteorite contains evidence of liquid water on Mars 742 million years ago

Self-reported screening helped reduce distressing symptoms for pediatric patients with cancer

Which risk factors are linked to having a severe stroke?

Opening borders for workers: Abe’s profound influence on Japan’s immigration regime

How skills from hospitality and tourism can propel careers beyond the industry

Research shows managers of firms handling recalls should review media scrutiny before deciding whether to lobby

New model system for the development of potential active substances used in condensate modifying drugs

How to reduce social media stress by leaning in instead of logging off

Pioneering research shows sea life will struggle to survive future global warming

In 10 seconds, an AI model detects cancerous brain tumor often missed during surgery 

Burden of RSV–associated hospitalizations in US adults, October 2016 to September 2023

Repurposing semaglutide and liraglutide for alcohol use disorder

[Press-News.org] Darapladib falls short in chronic coronary heart disease
Investigational drug targets inflammation's role in clogged arteries